Protein Science
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by VERLINDE, CLMJ.
Right arrow Articles by HOL, WGJ.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by VERLINDE, CLMJ.
Right arrow Articles by HOL, WGJ.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Protein Science, Vol 3, Issue 10 1670-1686, Copyright © 1994 by Cold Spring Harbor Laboratory Press


INVITED PAPER, SPECIAL SECTION IN HONOR OF MAX PERUTZ

Protein crystallography and infectious diseases

CLMJ. VERLINDE, E. A. MERRITT, FVD. AKKER, H. KIM, I. FEIL, L. F. DELBONI, S. C. MANDE, S. SARFATY, P. H. PETRA and WGJ. HOL
Departments of Biological Structure and Biochemistry, Biomolecular Structure Program and Howard Hughes Medical Institute, University of Washington, Seattle Washington 98195

The current rapid growth in the number of known 3-dimensional protein structures is producing a database of structures that is increasingly useful as a starting point for the development of new medically relevant molecules such as drugs, therapeutic proteins, and vaccines. This development is beautifully illustrated in the recent book, Protein structure: New approaches to disease and therapy (Perutz, 1992). There is a great and growing promise for the design of molecules for the treatment or prevention of a wide variety of diseases, an endeavor made possible by the insights derived from the structure and function of crucial proteins from pathogenic organisms and from man. We present here 2 illustrations of structure-based drug design. The first is the prospect of developing anti-trypanosomal drugs based on crystallographic, ligand-binding, and molecular modeling studies of glycolytic glycosomal enzymes from Trypanosomatidae. These unicellular organisms are responsible for several tropical diseases, including African and American trypanosomiases, as well as various forms of leishmaniasis. Because the target enzymes are also present in the human host, this project is a pioneering study in selective design. The second illustrative case is the prospect of designing anti-cholera drugs based on detailed analysis of the structure of cholera toxin and the closely related Escherichia coli heat-labile enterotoxin. Such potential drugs can be targeted either at inhibiting the toxin's receptor binding site or at blocking the toxin's intracellular catalytic activity. Study of the Vibrio cholerae and E. coli toxins serves at the same time as an example of a general approach to structure-based vaccine design. These toxins exhibit a remarkable ability to stimulate the mucosal immune system, and early results have suggested that this property can be maintained by engineered fusion proteins based on the native toxin structure. The challenge is thus to incorporate selected epitopes from foreign pathogens into the native framework of the toxin such that crucial features of both the epitope and the toxin are maintained. That is, the modified toxin must continue to evoke a strong mucosal immune response, and this response must be directed against an epitope conformation characteristic of the original pathogen.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
J. Biol. Chem.Home page
A. L. Horstman, S. J. Bauman, and M. J. Kuehn
Lipopolysaccharide 3-Deoxy-D-manno-octulosonic Acid (Kdo) Core Determines Bacterial Association of Secreted Toxins
J. Biol. Chem., February 27, 2004; 279(9): 8070 - 8075.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. L. Horstman and M. J. Kuehn
Bacterial Surface Association of Heat-labile Enterotoxin through Lipopolysaccharide after Secretion via the General Secretory Pathway
J. Biol. Chem., August 30, 2002; 277(36): 32538 - 32545.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
K. Maithal, G. Ravindra, H. Balaram, and P. Balaram
Inhibition of Plasmodium falciparum Triose-phosphate Isomerase by Chemical Modification of an Interface Cysteine. ELECTROSPRAY IONIZATION MASS SPECTROMETRIC ANALYSIS OF DIFFERENTIAL CYSTEINE REACTIVITIES
J. Biol. Chem., July 5, 2002; 277(28): 25106 - 25114.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. L. Horstman and M. J. Kuehn
Enterotoxigenic Escherichia coli Secretes Active Heat-labile Enterotoxin via Outer Membrane Vesicles
J. Biol. Chem., April 21, 2000; 275(17): 12489 - 12496.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
X.-G. Gao, E. Maldonado, R. Perez-Montfort, G. Garza-Ramos, M. T. de Gomez-Puyou, A. Gomez-Puyou, and A. Rodriguez-Romero
Crystal structure of triosephosphate isomerase from Trypanosoma cruzi in hexane
PNAS, August 31, 1999; 96(18): 10062 - 10067.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by The Protein Society.